Questions over AstraZeneca's COVID-19 vaccine data risk delaying approval

Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news